BNP Paribas Financial Markets Has $41,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

BNP Paribas Financial Markets trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 38.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 11,540 shares of the company’s stock after selling 7,286 shares during the period. BNP Paribas Financial Markets’ holdings in Aquestive Therapeutics were worth $41,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. New York State Common Retirement Fund grew its stake in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after buying an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Aquestive Therapeutics during the fourth quarter worth about $44,000. PKS Advisory Services LLC acquired a new stake in Aquestive Therapeutics during the fourth quarter worth about $63,000. China Universal Asset Management Co. Ltd. acquired a new stake in Aquestive Therapeutics during the fourth quarter worth about $69,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Aquestive Therapeutics by 16.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after buying an additional 3,821 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AQST has been the topic of a number of research analyst reports. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research note on Monday. They issued an “outperform” rating and a $7.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Lake Street Capital reduced their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.14.

Aquestive Therapeutics Trading Up 13.2%

AQST opened at $3.18 on Wednesday. The company’s 50 day moving average is $2.65 and its 200-day moving average is $3.15. The company has a market cap of $315.86 million, a P/E ratio of -7.07 and a beta of 2.02. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. On average, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.